QTX125 TFA|西域试剂

QTX125 TFA,98.97%

产品编号：Bellancom-120448A| 分子式：C₂₅H₂₀F₃N₃O₇| 分子量：531.44

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-120448A	￥3800.00	杭州北京（现货）
Bellancom-120448A	￥6000.00	杭州北京（现货）
Bellancom-120448A	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

QTX125 TFA

产品介绍

QTX125 TFA 是一种有效且高度选择性的 HDAC6 抑制剂。与其他 HDAC 相比，QTX125 对 HDAC6 具有出色的选择性。QTX125 TFA 具有抗肿瘤作用。

生物活性

QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.

体外研究

QTX125 (25-500 nM; 24-48 hours) TFA treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP.
In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 TFA (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin.
QTX125 TFA has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells
Concentration:	25 nM, 50 nM, 100 nM, 500 nM
Incubation Time:	24 hours, 48 hours
Result:	Inhibited annexin V/propidium iodide double staining.

Western Blot Analysis

Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells
Concentration:	25 nM, 50 nM, 100 nM, 500 nM
Incubation Time:	24 hours
Result:	Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP.

体内研究
(In Vivo)

QTX125 TFA (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing REC-1 or MINO cells
Dosage:	60 mg/kg
Administration:	Intraperitoneal administration; daily dosing for 5 days; for 4 weeks
Result:	Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice.

体内研究

QTX125 TFA (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing REC-1 or MINO cells
Dosage:	60 mg/kg
Administration:	Intraperitoneal administration; daily dosing for 5 days; for 4 weeks
Result:	Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice.

体内研究

QTX125 TFA (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing REC-1 or MINO cells
Dosage:	60 mg/kg
Administration:	Intraperitoneal administration; daily dosing for 5 days; for 4 weeks
Result:	Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (235.21 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8817 mL	9.4084 mL	18.8168 mL
5 mM	0.3763 mL	1.8817 mL	3.7634 mL
10 mM	0.1882 mL	0.9408 mL	1.8817 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.91 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.91 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.91 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.91 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明